Identifai-Genetics, a Tel Aviv, Israel-based developer of AI-based solutions for non-invasive fetal DNA sequencing, raised USD 3.3M in Post-Seed funding.
The round was led by eHealth Ventures, and included Dr. Ron Sabar.
The company intends to use the funds to expand operations and R&D efforts.
Co-founded in 2021 by Shizim Innovation Center, led by Mr. Yossi Bornstein, who serves as Identifai’s chairman, as well as Prof. Noam Shomron (CSO), Dr. Tom Rabinowitz (CTO) and Dr. Amir Beker (CEO), Identifai is a digital bioinformatics company that offers solutions for the non-invasive detection of fetal genetic disorders, at an early stage of the pregnancy, using a risk-free blood test from the mother.
Identifai has recently engaged HcFocusTM, founded by Dr. Susan Gross, who will serve as Chief Strategic Advisor to the company. Dr Gross is a global expert in the field of non-invasive prenatal screening, formerly the Chief Medical Officer of Natera Inc. (a NASDAQ traded company), a world leader in cell-free DNA testing. In addition, Dr. Gross has served on multiple guideline committees specific to prenatal screening, following many years as a professor of clinical obstetrics & gynecology, pediatrics and genetics at the Albert Einstein College of Medicine in New York City.
The company has raised over $6M in equity investments and R&D grants.
FinSMEs
21/04/2023